One hundred and ninety five consecutive, potentially curative resections for adenocarcinoma of the stomach were performed in one surgical department between 1970 and 1989: 76 patients underwent gastrectomy with splenectomy and 119 gastrectomy without splenectomy. Operative mortality was 12% after gastrectomy with splenectomy, but only 2/5% after gastrectomy without splenectomy (p<0.05). Postoperative complications were also significantly more common when splenectomy was combined with gastrectomy (41% v 14%, p<O.Ol). Cumulative five year survival was 45% after gastrectomy with splenectomy, compared with 71% after gastrectomy alone (p<0.01). When the results of the two groups of patients were compared, stage for pathological stage, no evidence was found that splenectomy improved survival. Application of Cox's proportional hazards model, which makes allowance for other variables such as the T and N stages, showed that splenectomy had an adverse influence on patients' survival. Splenectomy does not benefit the patient and its routine use in the course of radical resections for carcinoma of the stomach should be abandoned. (Gut 1995; 36: 684-690) 
It is widely assumed and confidently asserted at Improvements in surgical technique may take the form of more radical resections, as in the case of extended (R2) lymphadenectomy for gastric cancer. Paradoxically, significant advances may occasionally result from the adoption of less radical rather than more radical surgical methods, which incorporate new knowledge of the value to the host of the structures thus preserved. For example, the increasing understanding of the part played by the spleen in the immunological defences of the body and in the prevention of sepsis prompted this reappraisal of the value of routine removal of the spleen, en bloc with the stomach, in the course of radical, potentially curative resection for gastric cancer. Our hypothesis was that splenectomy performed routinely in these circumstances would probably do the patient more harm than good.
Methods
Patients and operative procedures Between January 1970 and December 1989, 493 consecutive patients with adenocarcinoma of the stomach were treated in the University Department of Surgery of the General Infirmary at Leeds. In 207 of them it proved possible to perform a radical, potentially curative resection, in which all visible tumour was removed and the proximal and distal resection margins were free of tumour on microscopic examination. Of the 207 patients, 76 underwent total gastrectomy with splenectomy, 21 total gastrectomy without splenectomy, and 98 subtotal gastrectomy without splenectomy. The remaining 12 patients underwent IvorLewis oesophagogastrectomy and are not considered further in this analysis. Fourteen of 76 patients who underwent total gastrectomy with splenectomy also underwent distal pancreatectomy.
Since 1978, the standard surgical approach has consisted of wide gastric resection with a radical (R2) lymphadenectomy, in which the second tier of lymph nodes (N2), beyond the perigastric nodes (NI), is removed.3 In those patients who underwent a radical (R2) total gastrectomy, this entailed the removal of the spleen and distal pancreas, as advocated by the Japanese. In the early 1 980s, however, we noticed an increase in operative mortality and morbidity in patients who had their spleen and pancreas resected. We therefore modified our approach in the mid 1980s to conserve the spleen and pancreas wherever possible, while still maintaining a radical lymph node clearance. These two organs were still resected, however, if the tumour was close to or directly invading either the tail of pancreas or splenic hilum.
All total gastrectomy procedures were accompanied by Roux-en-Y reconstruction with a 40-50 cm Roux loop of jejunum. Polya reconstruction was normally used after subtotal gastrectomy. The tumours were staged in accordance with the 1987 unified International TNM classification for gastric cancer.4 Table I gives further details of the patients. It is important to note that patients who underwent gastrectomy with splenectomy had more advanced tumours, on average, than patients who did not undergo splenectomy. Fourteen patients underwent distal pancreatectomy in addition to splenectomy: operative mortality in these patients was 21% (three of 14), while mortality was 10% (six of 62) after gastrectomy and splenectomy without pancreatectomy (NS).
Three other patients died between one and three months after operation: one after subtotal gastrectomy and two after total gastrectomy and splenectomy. Three month operative mortality was thus 7.5%: 14% after gastrectomy with splenectomy and 3% after gastrectomy without splenectomy (p<0. 01).
Postoperative morbidity Forty eight patients (25%) developed significant postoperative complications. The incidence of complications was 41% after gastrectomy with splenectomy, 5% after total gastrectomy alone, and 16% after subtotal gastrectomy (Table IV) Tables I and II. gastrectomy with splenectomy, five year survival was only 45%/o (p<001, Fig 1) . When operative deaths were included in the analysis, the difference in five year survival between the two groups of patients -those with or without splenectomy -was even greater: 67% after gastrectomy alone, but only 39% after gastrectomy with splenectomy (p<0 001): overall five year survival was then 55%. Five year survival after total gastrectomy without splenectomy (78%) did not differ significantly from five year survival after subtotal gastrectomy without splenectomy (69%).
Influence of splenectomy on survival, stage for pathological stage -it is not surprising that five year survival should have been poorer among patients who underwent splenectomy than among patients who did not, because the pathological stage of the tumours in the first group tended to be more advanced (Table I) . We therefore compared five year survival, after exclusion of postoperative deaths, of the two groups of patients, stage for pathological stage (Table V) . Among patients with stage I tumours, five year survival was 91% in both groups: splenectomy had no influence on survival. That was true also for patients with stage II tumours, among whom 72% of those who had undergone gastrectomy without splenectomy and 69% of those who had undergone gastrectomy with splenectomy survived for five years. In stage III, however, a greater proportion of patients who had undergone gastrectomy without splenectomy survived for five years, than of patients who had undergone gastrectomy with splenectomy (34% and 25% respectively, p<005) (Fig 2) .
Multivariate analysis -when all the factors listed in Table VI were analysed by Cox's proportional hazards model, metastasis to lymph nodes (hazard ratio 6.5) and depth of tumour penetration through the wall of the stomach (41) 1 (5) 15 (15) (hazard ratio 3.3) were found, as expected, to be the most important predictors of survival. However, splenectomy was also found to be a significant predictor of poor survival (hazard ratio 1.5). No evidence was found that the extent of the gastric resection -total or subtotal -the seniority of the operating surgeon or the patient's age influenced survival. The spleen itself is seldom affected by gastric cancer, though the lymph nodes in the hilum of the spleen are sometimes affected. In the past, the knowledge that these nodes may be involved by tumour led to the widespread, uncritical assumption that the spleen and its hilar nodes should always be removed en bloc with the stomach in the course of radical, potentially curative resection for carcinoma of the body, fundus, and cardia of the stomach. In the 1990s, because of the explosion of knowledge about the immunological functions of the spleen, which protect the host against infection and perhaps also against tumour micrometastases, such assumptions must be questioned. The burden of proof now lies with those who would remove the spleen, rather than those who would preserve it. That is, gastrectomy with splenectomy should not be accepted as the standard 'curative' operative procedure for gastric cancer until it can be shown that the addition of splenectomy confers significant advantage on the patient, either in terms of lower operative mortality or improved longtern survival.
Morbidity and mortality
We found that when the spleen was removed in the course of radical, potentially curative resection for gastric carcinoma, operative mortality was much higher than when the spleen was preserved (12% v 2-5%, p<0 05) and postoperative morbidity was much greater (41% v 14%, p<0001). These figures are admittedly somewhat biased, because patients who underwent gastrectomy with splenectomy had more advanced disease, on average, than patients who underwent gastrectomy alone (Table I) . Presumably, therefore, they underwent more extensive and hazardous operative procedures.
The results among patients who belonged to the same pathological stage and who either had, or had not, undergone splenectomy, were therefore examined. As Table V shows, the results were consistently better in patients in whom the spleen had been preserved. For example, in patients with stage I disease, both operative mortality (14% v 2%) and postoperative morbidity (37% V 15%) were considerably greater in patients who had undergone gastrectomy with splenectomy than in patients who had undergone gastrectomy alone. In stage III, operative mortality (15% v 5%) and postoperative morbidity (49% v 14%) were again found gastrectomies with preservation of the spleen and pancreas, and the operative mortality in this group of patients was 0% (Table II) , compared with an overall operative mortality of tomy 5% in the 1980s. Yoshino et al 19 found that five year survival was 47% after radical total gastrectomy and splenectomy, compared with 61% after total gastrectomy alone, among patients who underwent resection for locally advanced tumours of the proximal stomach. Likewise, Koga et al17 found that five year survival in patients with stage III disease was greater among those who underwent gastrectomy without splenectomy than among those who underwent gastrectomy with splenectomy (41% v 20% respectively). In this [15] [16] [17] An adverse effect of splenectomy on survival has also been reported in patients with colorectal cancer who have lymph nodes affected with tumour. For example, Davis et al 20 found that in patients who had undergone potentially curative resection for Dukes's C cancer of the colon, splenectomy was associated with decreased five year survival: 52% without splenectomy compared with only 19% if splenectomy had been performed. In that study, however, blood transfusion requirements among patients who had undergone splenectomy were greater than in those who had not, and this could have influenced survival adversely in the splenectomy group. Unfortunately, information on the requirement for blood transfusion of the patients in our study was insufficient to allow us to assess the influence of this factor on survival.
Our study differs from previous reports in that we found by multivariate analysis that splenectomy was an independent predictor of poor outcome, in the form of death from recurrent cancer (hazard ratio 1.5). Admittedly, the adverse effect of splenectomy on survival was comparatively weak compared with the profound influence exerted by depth of tumour penetration and the presence of lymph node metastases (Table VI) , as Maruyama2' and many others have shown previously. While accepting that this analysis has all the inherent problems associated with retrospective studies and that the two groups of patients were not matched prospectively stage for pathological stage, we have certainly failed to show that removal of the spleen confers any benefit on the patient.
Theoretical considerations in favour of and against splenectomy Why then has it been accepted for so long that the spleen (and sometimes the tail of the pancreas) should be included in radical resections for gastric cancer, at least for tumours that are situated in the body or fundus of the stomach? As long ago as 1941,22 the nodes in the hilum of the spleen were reported to be affected by metastatic spread from gastric cancer. Japanese and German authors have emphasised how important it is to remove both the first and second tier of lymph nodes in the course of potentially curative resection for gastric cancer.3 23 24 The nodes at the hilum of the spleen, however, are usually N2 nodes (nodes of the second tier), unless the tumour is located on the greater curvature of the stomach, near the splenic hilum. In this study, 87% of patients with N2 nodal involvement had primary tumours that had also penetrated through the serosa (T3), and few patients with such T3N2 tumours survive for five years, even after the most radical types of gastric resection. 25 It is patients whose cancers are located in the proximal third of the stomach who have the greatest probability of having affected lymph nodes in the hilum of the spleen. Even among these patients, however, only 3% of patients with T2 tumours and 13% of patients with T3 tumours have affected splenic hilar nodes, though when the tumour is on the greater curvature of the stomach, close to the splenic hilum, 26% of patients have positive splenic hilar nodes. showed that the risk of thromboembolic complications was considerably greater in patients who underwent splenectomy, whether malignant disease was present or not. The increased risk of thromboembolism after splenectomy is thought to result from greater blood viscosity and to an increase in the platelet count. 36 Finally, longterm depression of T cell proliferation, a measure of the cell mediated immune system, has been shown in patients after splenectomy.37 This impaired proliferative response to mitogens such as phytohaemagglutinin may point to a more general impairment of patients' immune system after splenectomy, which could diminish their ability to lyse tumour micrometastases. The presence of the spleen has been shown to be essential if immunomodulation with the streptococcal preparation, OK-432, is to be effective when used as adjuvant therapy in gastric cancer.38 Precisely how OK-432 acts and why the spleen should be necessary for its activity are unclear. It may be no coincidence, however, that OK-432 is a streptococcal derivative, as the spleen is essential for the immune response to streptococcal infection in humans.
In summary, an important indictment of surgery for gastric cancer in Britain is that the operative mortality is still too high, though some improvement has been noted in recent years.39 In the largest survey of gastric cancer ever undertaken in Britain,40 operative mortality after potentially curative resection was 16%, while after palliative resection the mortality was 25%. Radical (R2) clearance of lymph nodes is important for the survival of patients with stage II and IIIa disease who undergo potentially curative resection, as Japanese21 24 and German25 surgeons have shown. Although in expert hands such radical resections can be accomplished with an operative mortality of two to five per cent,7 21 25 prospective randomised trials in the Netherlands41 and in the United Kingdom42 suggest that they may be associated with increased postoperative morbidity and mortality, and they might be rendered safer if the spleen and tail of pancreas were preserved. To reduce the operative mortality from more than 10% to less than 5% would, in itself, be 
